DrugPatentWatch Database Preview
Sanofi-aventis U.s. Llc Company Profile
Email this page to a colleague
» See Plans and PricingUS Patents for Sanofi-aventis U.s. Llc
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi-aventis U.s. Llc | LANTUS | insulin glargine | INJECTION, SOLUTION | 021081 | 1 | 2017-06-04 | 9,982,029 | SANOFI (Paris, FR) | 2035-07-10 | search | ||
| Sanofi-aventis U.s. Llc | LANTUS | insulin glargine | INJECTION, SOLUTION | 021081 | 1 | 2017-06-04 | 9,964,545 | WATERS TECHNOLOGIES CORPORATION (Milford, MA) | 2032-04-18 | search | ||
| Sanofi-aventis U.s. Llc | LANTUS | insulin glargine | INJECTION, SOLUTION | 021081 | 1 | 2017-06-04 | 9,950,039 | SANOFI-AVENTIS DEUTSCHLAND GMBH (Frankfurt am Main, DE) | 2034-12-12 | search | ||
| Sanofi-aventis U.s. Llc | LANTUS | insulin glargine | INJECTION, SOLUTION | 021081 | 1 | 2017-06-04 | 9,931,380 | 2035-02-19 | search | |||
| Sanofi-aventis U.s. Llc | LANTUS | insulin glargine | INJECTION, SOLUTION | 021081 | 1 | 2017-06-04 | 9,884,094 | Novo Nordisk A/S (Bagsvaerd, DK) | 2032-05-01 | search | ||
| Sanofi-aventis U.s. Llc | LANTUS | insulin glargine | INJECTION, SOLUTION | 021081 | 1 | 2017-06-04 | 9,822,158 | Merck Sharp & Dohme Corp. (Rahway, NJ) | 2033-12-04 | search | ||
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
Similar Applicant Names
Companies are sometimes listed under multiple names.
This search can help find similar names.
This search can help find similar names.
